Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors.

ABSTRACT: Recent developments in gene engineering technologies have drastically improved the therapeutic treatment options for cancer patients. The use of effective chimeric antigen receptor T (CAR-T) cells and recombinant T cell receptor engineered T (rTCR-T) cells has entered the clinic for treatment of hematological malignancies with promising results. However, further fine-tuning, to improve functionality and safety, is necessary to apply these strategies for the treatment of solid tumors. The immunosuppressive microenvironment, the surrounding stroma, and the tumor heterogeneity often results in poor T cell reactivity, functionality, and a diminished infiltration rates, hampering the efficacy of the treatment. The focus of this review is on recent advances in rTCR-T cell therapy, to improve bot

SUBMITTER: Lo Presti V 

PROVIDER: S-EPMC7761868 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature